Sumatriptan succinate is a pharmaceutical compound primarily used in the treatment of migraine headaches. It is a selective agonist for serotonin receptors, specifically the 5-HT_1B and 5-HT_1D subtypes, which play a crucial role in vasoconstriction and the modulation of neurotransmitter release. The substance is a white to off-white crystalline powder, soluble in water, and has a molecular formula that reflects its complex structure, which includes a sulfonamide group. Sumatriptan succinate is typically administered orally or via injection, with its pharmacokinetics characterized by rapid absorption and a relatively short half-life. The compound is known for its efficacy in alleviating migraine symptoms, although it may cause side effects such as dizziness, nausea, or sensations of tightness. As with any medication, it is essential to consider contraindications and potential interactions with other drugs. Overall, Sumatriptan succinate represents a significant advancement in migraine therapy, providing relief for many patients suffering from this debilitating condition.

Sumatriptan succinate

103628-48-4: 1-[3-[2-(Dimethylamino)ethyl]-1H-indol-5-yl]-N-methylmethanesulfonamide; butanedioic acid, 1H-Indole-5-methanesulfonamide, 3-[2-(dimethylamino)ethyl]-N-methyl-, butanedioate (1:1), 3-(2-(Dimethylamino)ethyl)-N-methylindole-5-methanesulfonamide succinate (1:1), Butanedioic acid, compd. with 3-[2-(dimethylamino)ethyl]-N-methyl-1H-indole-5-methanesulfonamide (1:1), Gr 43175C, Imigran, Imigrane, Imiject, Imitrex, Megrelan, Migragesin, Sumagraine, Suminat, Sumitrex, Treximet, Sumatriptan succinate

CAS 103628-48-4: Sumatriptan succinate

Sumatriptan Succinate

Ref: 45-1642201